Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background The decline of humoral response to COVID-19 vaccine led to authorise a booster dose. Here, we characterised the kinetics of B-cell and T-cell immune responses in patients with multiple sclerosis (PwMS) after the booster dose. Methods We enrolled 22 PwMS and 40 healthcare workers (HCWs) after 4–6 weeks from the booster dose (T3). Thirty HCWs and 19 PwMS were also recruited 6 months (T2) after the first dose. Antibody response was measured by anti-receptor-binding domain (RBD)-IgG detection, cell-mediated response by an interferon (IFN)-γ release assay (IGRA), Th1 cytokines and T-cell memory profile by flow cytometry. Results Booster dose increased anti-RBD-IgG titers in fingolimod-treated, cladribine-treated and IFN-β-treated patients, but not in ocrelizumab-treated patients, although antibody titres were lower than HCWs. A higher number of fingolimod-treated patients seroconverted at T3. Differently, T-cell response evaluated by IGRA remained stable in PwMS independently of therapy. Spike-specific Th1-cytokine response was mainly CD4+T-cell-mediated, and in PwMS was significantly reduced (p<0.0001) with impaired IL-2 production compared with HCWs at T3. In PwMS, total Th1 and IFN-γ CD4+T-cell responders to spike protein were increased from T2 to T3. Compared with HCWs, PwMS presented a higher frequency of CD4+and CD8+terminally differentiated effector memory cells and of CD4+effector memory (TEM) cells, independently of the stimulus suggesting the association of this phenotype with MS status. CD4+and CD8+TEMcell frequency was further increased at T3 compared with T2. Conclusions COVID-19 vaccine booster strengthens humoral and Th1-cell responses and increases TEMcells in PwMS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
- Date Crossref
- 15/12/2022
- Éditeur
- BMJ
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani pays non établi dans la noticeÉtablissement de santé
-
Fondazione Santa Lucia pays non établi dans la noticeÉtablissement de santé
-
Sapienza University of Rome pays non établi dans la noticeUniversité ou école supérieure
-
Carlo Forlanini Hospital pays non établi dans la noticeÉtablissement de santé
-
Bambino Gesù Children's Hospital pays non établi dans la noticeÉtablissement de santé
-
Translational Research Unit pays non établi dans la noticeStructure de recherche
-
University of Rome La Sapienza Department of Human Neurosciences pays non établi dans la noticeUniversité ou école supérieure
-
Santa Lucia Foundation Institute for Hospitalization and Care Scientific Neuroimmunology Unit pays non établi dans la noticeStructure de recherche
-
National Institute for Infectious Diseases Lazzaro Spallanzani Institute for Hospitalization and Care Scientific Unità Operativa Semplice (UOS) Professioni Sanitarie Tecniche pays non établi dans la noticeStructure de recherche
-
Laboratory of Virology pays non établi dans la noticeStructure de recherche
-
San Camillo Forlanini Hospital Department of Neurosciences pays non établi dans la noticeÉtablissement de santé
-
Clinical Division of Infectious Diseases pays non établi dans la noticeÉtablissement de santé
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Fondazione Santa Lucia et Sapienza University of Rome, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.